Cumulative Amount of Intravenous Lipid Intake and Parenteral Nutrition-Associated Cholestasis in Neonates with Gastrointestinal Surgical Disorders

Mazen M. Nayrouz; Sanjiv B. Amin

doi:10.1055/s-0033-1352481

American Journal of Perinatology, Inhaltsverzeichnis

Am J Perinatol 2014; 31(05): 419-424
DOI: 10.1055/s-0033-1352481

Original Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Cumulative Amount of Intravenous Lipid Intake and Parenteral Nutrition-Associated Cholestasis in Neonates with Gastrointestinal Surgical Disorders

Mazen M. Nayrouz

¹Division of Neonatology, Department of Pediatrics, Golisano Children's Hospital at Strong, University of Rochester Medical Center, Rochester, New York

,

Sanjiv B. Amin

¹Division of Neonatology, Department of Pediatrics, Golisano Children's Hospital at Strong, University of Rochester Medical Center, Rochester, New York

› Institutsangaben

Abstract

Objective To evaluate if cumulative amount of intravenous lipid (IL) intake is associated with severity of parenteral nutrition (PN)-associated cholestasis (PNAC) in neonates with gastrointestinal surgical disorders (GISD).

Study Design The authors performed a retrospective study including 36 neonates > 34 weeks gestational age with GISD. Neonates with metabolic liver disorders, chromosomal disorders, TORCH infections, which includes toxoplasmosis, other (syphilis, varicella-zoster, parvovirus B19), rubella, cytomegalovirus (CMV), and herpes, biliary tract anomalies, or direct hyperbilirubinemia (DHB) within first postnatal week were excluded.

Results There was no significant difference in clinical factors between three groups of neonates: (1) without PNAC (n = 13), (2) with mild-to-moderate PNAC (DHB 1–5 mg/dL, n = 12), and (3) with severe PNAC (DHB > 5 mg/dL or PNAC with elevated amino-transaminases, n = 11) except for duration of enteral starvation and PN. Using ordered logistic regression, cumulative amount of IL, glucose, and protein intake were independently associated with severity of PNAC (p < 0.05). Comparing macronutrients as predictors of severe PNAC using receiver operating characteristic curves, the area under the curve for IL (0.583) intake was significantly larger (p = 0.008) compared with intravenous protein (0.257) and glucose (0.431) intake.

Conclusions IL intake is associated with and is a better predictor of severity of PNAC in neonates with GISD.

Keywords

late preterm neonates - hepatic dysfunction - direct hyperbilirubinemia - lipid

Volltext

Referenzen

References
1 Klein CJ, Revenis M, Kusenda C, Scavo L. Parenteral nutrition-associated conjugated hyperbilirubinemia in hospitalized infants. J Am Diet Assoc 2010; 110 (11) 1684-1695
2 Willis TC, Carter BA, Rogers SP, Hawthorne KM, Hicks PD, Abrams SA. High rates of mortality and morbidity occur in infants with parenteral nutrition-associated cholestasis. JPEN J Parenter Enteral Nutr 2010; 34 (1) 32-37
3 Suchy FJ. Neonatal cholestasis. Pediatr Rev 2004; 25 (11) 388-396
4 Colomb V, Jobert-Giraud A, Lacaille F, Goulet O, Fournet JC, Ricour C. Role of lipid emulsions in cholestasis associated with long-term parenteral nutrition in children. JPEN J Parenter Enteral Nutr 2000; 24 (6) 345-350
5 Shin JI, Namgung R, Park MS, Lee C. Could lipid infusion be a risk for parenteral nutrition-associated cholestasis in low birth weight neonates?. Eur J Pediatr 2008; 167 (2) 197-202
6 Clayton PT, Bowron A, Mills KA, Massoud A, Casteels M, Milla PJ. Phytosterolemia in children with parenteral nutrition-associated cholestatic liver disease. Gastroenterology 1993; 105 (6) 1806-1813
7 Javid PJ, Malone FR, Dick AA , et al. A contemporary analysis of parenteral nutrition-associated liver disease in surgical infants. J Pediatr Surg 2011; 46 (10) 1913-1917
8 Beath SV, Davies P, Papadopoulou A , et al. Parenteral nutrition-related cholestasis in postsurgical neonates: multivariate analysis of risk factors. J Pediatr Surg 1996; 31 (4) 604-606
9 Schulman J, Stricof R, Stevens TP , et al; New York State Regional Perinatal Care Centers. Statewide NICU central-line-associated bloodstream infection rates decline after bundles and checklists. Pediatrics 2011; 127 (3) 436-444
10 American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004; 114 (1) 297-316
11 Teitelbaum DH, Han-Markey T, Drongowski RA , et al. Use of cholecystokinin to prevent the development of parenteral nutrition-associated cholestasis. JPEN J Parenter Enteral Nutr 1997; 21 (2) 100-103
12 Fok TF, Chui KK, Cheung R, Ng PC, Cheung KL, Hjelm M. Manganese intake and cholestatic jaundice in neonates receiving parenteral nutrition: a randomized controlled study. Acta Paediatr 2001; 90 (9) 1009-1015
13 Koletzko B, Goulet O, Hunt J, Krohn K, Shamir R ; Parenteral Nutrition Guidelines Working Group; European Society for Clinical Nutrition and Metabolism; European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN); European Society of Paediatric Research (ESPR). 1. Guidelines on Paediatric Parenteral Nutrition of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the European Society for Clinical Nutrition and Metabolism (ESPEN), Supported by the European Society of Paediatric Research (ESPR). J Pediatr Gastroenterol Nutr 2005; 41 (Suppl. 02) S1-S87
14 La Scala GC, Le Coultre C, Roche BG, Bugmann P, Belli DC. The addition of lipids increases the total parenteral nutrition-associated cholestasis in the rat. Eur J Pediatr Surg 1993; 3 (4) 224-227
15 Haynes MJ, Stahlman MT, Bradley YA, Jacqueline CJ. Hepatic pathology in extremely low birth weight baboons receiving long term intralipid. Pediatr Res 2002; 1672A
16 Cavicchi M, Beau P, Crenn P, Degott C, Messing B. Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med 2000; 132 (7) 525-532
17 Hsieh MH, Pai W, Tseng HI, Yang SN, Lu CC, Chen HL. Parenteral nutrition-associated cholestasis in premature babies: risk factors and predictors. Pediatr Neonatol 2009; 50 (5) 202-207
18 Steinbach M, Clark RH, Kelleher AS , et al; Pediatrix Amino-Acid Study Group. Demographic and nutritional factors associated with prolonged cholestatic jaundice in the premature infant. J Perinatol 2008; 28 (2) 129-135
19 Cober MP, Teitelbaum DH. Prevention of parenteral nutrition-associated liver disease: lipid minimization. Curr Opin Organ Transplant 2010; 15 (3) 330-333
20 Hallikainen M, Huikko L, Kontra K , et al. Effect of parenteral serum plant sterols on liver enzymes and cholesterol metabolism in a patient with short bowel syndrome. Nutr Clin Pract 2008; 23 (4) 429-435
21 Carter BA, Shulman RJ. Mechanisms of disease: update on the molecular etiology and fundamentals of parenteral nutrition associated cholestasis. Nat Clin Pract Gastroenterol Hepatol 2007; 4 (5) 277-287
22 Carter BA, Taylor OA, Prendergast DR , et al. Stigmasterol, a soy lipid-derived phytosterol, is an antagonist of the bile acid nuclear receptor FXR. Pediatr Res 2007; 62 (3) 301-306
23 Neuzil J, Darlow BA, Inder TE, Sluis KB, Winterbourn CC, Stocker R. Oxidation of parenteral lipid emulsion by ambient and phototherapy lights: potential toxicity of routine parenteral feeding. J Pediatr 1995; 126 (5 Pt 1) 785-790
24 Baird LL. Protecting TPN and lipid infusions from light: reducing hydroperoxides in NICU patients. Neonatal Netw 2001; 20 (2) 17-22
25 Gura KM, Lee S, Valim C , et al. Safety and efficacy of a fish-oil-based fat emulsion in the treatment of parenteral nutrition-associated liver disease. Pediatrics 2008; 121 (3) e678-e686
26 Park KT, Nespor C, Kerner Jr J. The use of Omegaven in treating parenteral nutrition-associated liver disease. J Perinatol 2011; 31 (Suppl. 01) S57-S60
27 Puder M, Valim C, Meisel JA , et al. Parenteral fish oil improves outcomes in patients with parenteral nutrition-associated liver injury. Ann Surg 2009; 250 (3) 395-402
28 Grimminger F, Wahn H, Mayer K, Kiss L, Walmrath D, Seeger W. Impact of arachidonic versus eicosapentaenoic acid on exotonin-induced lung vascular leakage: relation to 4-series versus 5-series leukotriene generation. Am J Respir Crit Care Med 1997; 155 (2) 513-519
29 Wanten GJ, Calder PC. Immune modulation by parenteral lipid emulsions. Am J Clin Nutr 2007; 85 (5) 1171-1184
30 Beale EF, Nelson RM, Bucciarelli RL, Donnelly WH, Eitzman DV. Intrahepatic cholestasis associated with parenteral nutrition in premature infants. Pediatrics 1979; 64 (3) 342-347
31 Puligandla PS, Janvier A, Flageole H, Bouchard S, Mok E, Laberge JM. The significance of intrauterine growth restriction is different from prematurity for the outcome of infants with gastroschisis. J Pediatr Surg 2004; 39 (8) 1200-1204
32 Balistreri WF. Immaturity of hepatic excretory function and the ontogeny of bile acid metabolism. J Pediatr Gastroenterol Nutr 1983; 2 (Suppl. 01) S207-S214
33 Aynsley-Green A. Hormones and postnatal adaptation to enteral nutrition. J Pediatr Gastroenterol Nutr 1983; 2 (3) 418-427
34 Clark RH, Chace DH, Spitzer AR ; Pediatrix Amino Acid Study Group. Effects of two different doses of amino acid supplementation on growth and blood amino acid levels in premature neonates admitted to the neonatal intensive care unit: a randomized, controlled trial. Pediatrics 2007; 120 (6) 1286-1296
35 Vileisis RA, Inwood RJ, Hunt CE. Prospective controlled study of parenteral nutrition-associated cholestatic jaundice: effect of protein intake. J Pediatr 1980; 96 (5) 893-897
36 Costa S, Maggio L, Sindico P, Cota F, De Carolis MP, Romagnoli C. Preterm small for gestational age infants are not at higher risk for parenteral nutrition-associated cholestasis. J Pediatr 2010; 156 (4) 575-579
37 Sondheimer JM, Asturias E, Cadnapaphornchai M. Infection and cholestasis in neonates with intestinal resection and long-term parenteral nutrition. J Pediatr Gastroenterol Nutr 1998; 27 (2) 131-137